Lilly aims for technology synergies with unified genetic medicines group

Eli Lilly is expanding its commitment to genetic therapies through the newly launched Lilly Institute for Genetic Medicine, which restructures its DNA and RNA therapies under one group to synergize technologies across the related modalities. The institute told BioCentury it will be shopping for new delivery technologies.

The Lilly Institute for Genetic Medicine is launching with an investment of about $700 million to establish a new site in Boston, and is designed to combine the internal RNA therapy capabilities at Eli Lilly and Co. (NYSE:LLY) with the gene therapy and gene editing capabilities the pharma brought in through its 2020 acquisition of Prevail Therapeutics Inc. for about $880 million. ...